HK1080517A1 - Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use - Google Patents

Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use

Info

Publication number
HK1080517A1
HK1080517A1 HK06103163A HK06103163A HK1080517A1 HK 1080517 A1 HK1080517 A1 HK 1080517A1 HK 06103163 A HK06103163 A HK 06103163A HK 06103163 A HK06103163 A HK 06103163A HK 1080517 A1 HK1080517 A1 HK 1080517A1
Authority
HK
Hong Kong
Prior art keywords
methods
factor viii
amino acid
nucleic acid
sequences encoding
Prior art date
Application number
HK06103163A
Other languages
English (en)
Inventor
John S Lollar
Original Assignee
Expression Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expression Therapeutics Llc filed Critical Expression Therapeutics Llc
Publication of HK1080517A1 publication Critical patent/HK1080517A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK06103163A 2001-10-05 2006-03-13 Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use HK1080517A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32738801P 2001-10-05 2001-10-05
PCT/US2002/033403 WO2003031598A2 (en) 2001-10-05 2002-10-07 Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use

Publications (1)

Publication Number Publication Date
HK1080517A1 true HK1080517A1 (en) 2006-04-28

Family

ID=23276347

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06103163A HK1080517A1 (en) 2001-10-05 2006-03-13 Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use

Country Status (10)

Country Link
US (3) US7635763B2 (xx)
EP (1) EP1572889B1 (xx)
JP (2) JP4634036B2 (xx)
AT (1) ATE417618T1 (xx)
AU (1) AU2002337901B2 (xx)
CA (1) CA2461443C (xx)
DE (1) DE60230456D1 (xx)
ES (1) ES2319745T3 (xx)
HK (1) HK1080517A1 (xx)
WO (1) WO2003031598A2 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
AU2002337901B2 (en) * 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
EP1636360A4 (en) 2003-06-03 2006-11-08 Cell Genesys Inc COMPOSITIONS AND METHODS FOR ENHANCED EXPRESSION OF RECOMBINANT POLYPEPTIDES FROM A SINGLE VECTOR USING A PEPTIDE CLEAVAGE SITE
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
PL1824988T3 (pl) 2004-11-12 2018-01-31 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
CA2724630A1 (en) * 2008-05-16 2009-11-19 Bayer Healthcare Llc Targeted coagulation factors and method of using the same
ES2721478T3 (es) * 2010-11-05 2019-07-31 Baxalta Inc Nueva variante del factor VIII antihemofílico que tiene actividad específica aumentada
ES2722209T3 (es) * 2011-07-08 2019-08-08 Bioverativ Therapeutics Inc Polipéptidos quiméricos e híbridos del Factor VIII, y métodos de uso de los mismos
US8986991B2 (en) * 2012-07-03 2015-03-24 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
EP3904376A1 (en) * 2013-06-24 2021-11-03 Xiao, Weidong Mutant factor viii compositions and methods
US10058624B2 (en) * 2015-04-16 2018-08-28 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
SG10202106307UA (en) 2015-11-13 2021-07-29 Takeda Pharmaceuticals Co Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
CN108602876B (zh) 2015-11-13 2022-07-05 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
MX2018012537A (es) 2016-04-15 2019-02-25 Univ Pennsylvania Terapia de genes para tratar hemofilia a.
EP3672605A1 (en) 2017-08-23 2020-07-01 Wake Forest University Health Sciences In utero transplantation of factor viii-expressing cells for treatment of hemophilia
US20200360441A1 (en) 2017-08-23 2020-11-19 Wake Forest University Health Sciences Post-natal transplantation of factor viii-expressing cells for treatment of hemophilia
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US11680109B2 (en) 2019-05-29 2023-06-20 Duke University Compositions and methods for detection and measurement of RNA modifications through targeted RNA editing
WO2022165390A1 (en) * 2021-01-29 2022-08-04 Expression Therapeutics, Llc Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
JPH08511423A (ja) * 1993-06-10 1996-12-03 ジェネティック セラピー，インコーポレイテッド 血友病治療のためのアデノウイルスベクター
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
JP2002517180A (ja) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
AU2002337901B2 (en) * 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use

Also Published As

Publication number Publication date
JP2011015698A (ja) 2011-01-27
WO2003031598A3 (en) 2006-01-05
EP1572889B1 (en) 2008-12-17
US7635763B2 (en) 2009-12-22
WO2003031598A2 (en) 2003-04-17
US8519111B2 (en) 2013-08-27
US20110077203A1 (en) 2011-03-31
JP4634036B2 (ja) 2011-02-16
US8188246B2 (en) 2012-05-29
ATE417618T1 (de) 2009-01-15
EP1572889A4 (en) 2006-09-06
US20120270266A1 (en) 2012-10-25
US20050118684A1 (en) 2005-06-02
ES2319745T3 (es) 2009-05-12
CA2461443A1 (en) 2003-04-17
JP2005518783A (ja) 2005-06-30
CA2461443C (en) 2011-07-12
EP1572889A2 (en) 2005-09-14
AU2002337901B2 (en) 2008-01-17
DE60230456D1 (de) 2009-01-29
JP5162635B2 (ja) 2013-03-13

Similar Documents

Publication Publication Date Title
HK1080517A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60225118D1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
MXPA03010103A (es) Peptidos y composiciones anti-microbianos.
MXPA03010079A (es) Formulaciones de oxicodona de administracion una vez al dia.
IL161016A (en) Polypeptides capable of ang-2 binding
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
PT1346034E (pt) Polipéptido da protease de clivagem do factor de von willebrand (vwf), ácido nucleico que codifica o polipéptido e utilização do polipéptido
IL173952A0 (en) Anti-angiogenic peptides and pharmaceutical compositions based thereon
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
DE60128701D1 (en) Claudin polypeptide
EP1634954A4 (en) PROTEASE, PROTEASE-CODING DNA AND PROCESS FOR PREPARING THE PROTEASE
SG142165A1 (en) Biologically active peptides
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
EP1566386A4 (en) GENE ASSOCIATED WITH CALVITIA AND POLYPEPTIDE CODE BY THIS GENE, AND USES THEREOF
DK2186898T3 (da) Blomstrings-induktion
WO2002077190A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
PL372827A1 (en) Nucleotide sequence coding for a tolc containing a heterologous amino acid sequence
WO2003048341A3 (en) Cap-gly domain structure and uses thereof
WO2002077193A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002074973A9 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002061088A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171007